Phase III Trial Validates Traditional Remedy
The study enrolled 219 patients with solid tumors—excluding blood cancers—who received papaya leaf extract after any round of chemotherapy. The results, now peer-reviewed and published, represent the first Phase III randomized clinical trial to demonstrate that CPLE improves recovery from chemotherapy-induced thrombocytopenia, according to the researchers. Dr Vikas Ostwal, professor in the Department of Medical Oncology at Tata Memorial Centre and the study’s principal investigator, explained that the extract works: patients’ platelet counts recover faster, meaning the next round of chemotherapy did not have to be delayed. He outlined the backdrop to the study, noting that the cost of medicines used to tackle the drop in platelet count post-chemotherapy was expensive; that sometimes patients came for their next round of chemotherapy with an improved platelet count, attributed to papaya leaf extract; and that there were some studies in India and Malaysia on the use of this extract in dengue, when platelet count fell.
The trial builds on a long history of traditional use. For generations, leaves of the Carica papaya plant have been used in folk medicine across parts of Asia for digestive troubles, skin conditions, and infections. In particular, they have long been a common remedy for dengue fever, a viral illness that can cause platelet counts to fall sharply. That traditional use provided a starting point for later scientific investigations. Over the past few decades, small studies and case reports, especially in India and Malaysia, hinted that the extract could help raise low platelet counts in dengue patients. That preliminary evidence led some oncologists to ask whether the same effect might help cancer patients experiencing a similar problem after chemotherapy. Researchers believe the extract contains compounds that may stimulate bone marrow to produce more platelets.
Cost Advantage Could Broaden Access
Dr Ostwal highlighted the economic implications of the finding. He told businessline that the papaya leaf extract medicine costs about ₹600 per cycle, whereas other drugs used for the same situation—including generic options—range from ₹6,000 to ₹30,000, and this is a recurring cost with each chemotherapy cycle. For patients paying out of pocket, the difference is significant. The Tata Memorial team emphasized that papaya leaf extract is not a cure for cancer; it is a targeted, affordable intervention for a specific side effect. Patients should consult their doctor for medical advice.
The study’s implications extend beyond India. Chemotherapy-induced thrombocytopenia is a global problem, and the cost of managing it with existing drugs can be prohibitive. A low-cost, plant-based option that has now been validated in a randomized Phase III trial offers a potential new tool for oncologists worldwide. However, the researchers caution that the extract has been tested only in solid tumors, not blood cancers, and that further studies may be needed to confirm the results in broader populations. For now, the evidence moves papaya leaf extract from folk remedy to evidence-based medicine, providing a practical option for patients who might otherwise face treatment delays or financial strain.
